NIH, FDA to tighten, review consulting rules as Congressional inquiry continues.
In this 12-page issue: Moonlighting by NCI and FDA scientists conflicted with CRADA work, House Subcommittee on Oversight and Investigations says.
HHS lawyer tells of pressure to allow former NCI Director Richard Klausner to receive $40,000 prize.
Former NIH Director Varmus calls for more oversight of conflicts, expresses surprise at growth of Title 42 program.
In Brief: ASCO awards career development grants.
Funding Opportunities listed.
Trending Stories
- Johnson and Johnson reaches $5.5B settlement deal over talc lawsuits
- Pour a Scotch, we’re talking clinical trials and prediction markets
- Maura Gillison, who identified the role of HPV in head and neck cancer, changing the standard of care, dies at 61
- Prediction markets now allow betting on clinical trial results, FDA decisions
It’s a high-risk bet: Insider trading, equipoise, integrity of research, public trust are at stake - Mount Sinai oncologist Krystal Cascetta, 40, and her infant daughter die in Somers, NY, home
- Trump plans a 200% tariff on imported generic drugs by 2029, raising fears of cancer drug shortages
“There is a reason why generics have been exempt from all the tariffs until now,” Brookings economist warns









